Advanced diabetic nephropathy disproportionately affects African-American females: Cross-sectional analysis and determinants of renal survival in an academic renal clinic

Ethnicity and Disease

Volumn 13, Issue 1, 2003, Pages 28-33

  Crook, Errol D ^a,b   Wofford, Perisco ^a   Oliver, Bonnie ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

African American; Angiotensin converting enzyme inhibitor; Diabetic nephropathy; Endstage renal disease; Female gender; Hypertension

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASODILATOR AGENT;

ADULT; AGE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE CLEARANCE; DEMOGRAPHY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIALYSIS; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; GENDER; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEGRO; PREDICTION; PREVALENCE; PROTEIN URINE LEVEL; RETROSPECTIVE STUDY; SEX RATIO; SURVIVAL; UNITED STATES;

ACADEMIC MEDICAL CENTERS; AFRICAN AMERICANS; CROSS-SECTIONAL STUDIES; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MISSISSIPPI; OBESITY; SURVIVAL ANALYSIS; WOMEN'S HEALTH;

EID: 0037412862     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Crook ED. Diabetic nephropathy in African Americans. Am J Hypertens. 2001;14:132S-138S.
2. US Renal Data System. USRDS 1998 Annual Data Report. Bethesda, Md: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1998.
3. Crook ED, Harris J, Oliver B, et al. Endstage renal disease due to diabetic nephropathy in Mississippi: an examination of factors influencing renal survival in a population prone to late referral. J Invest Med. 2001;49:284-291.
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
5. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive Type II diabetic patients. Ann Intern Med. 1993;118:577-581.
6. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindras RE. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis. 2000;35: 695-707.
7. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ. 1982;285:685-689.
8. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces the rate of decline in kidney function in diabetic nephropathy. Lancet. 1983;1:1175-1179.
9. Chaiken RL, Palmisano J, Norton ME, et al. Interaction of hypertension and diabetes on renal function in Black NIDDM subjects. Kidney Int. 1995;47:1697-1702.
10. Brancati FL, Kao WH, Folsom AR, et al. Incident Type 2 diabetes mellitus in African-American and White adults: the Atherosclerosis Risk in Communities Study. JAMA. 2000;283:2253-2259.
11. Kohler KA, McClellan WM, Ziemer DC, et al. Risk factors for microalbuminuria in Black Americans with newly diagnosed Type 2 diabetes. Am J Kidney Dis. 2000;36:903.
12. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281:1291-1297.
13. Krop JS, Coresh J, Chambless LE, et al. A community-based study of explanatory factors for the excess risk for early renal function decline in Blacks vs Whites with diabetes: the Atherosclerosis Risk in Communities Study. Arch Intern Med 1999;159:1777-1783.
14. Sempos CT, Bild DE, Manolio TA. Overview of the Jackson Heart Study: a study of cardiovascular diseases in African-American men and women. Am J Med Sci. 1999;317:142-146.
15. Joint National Committee VI. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
16. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000;36:646-661.
17. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
18. Ihle BU, Whitworth JA, Shaninfar S, Cnaan A, Kincaid-Smith PS, Becker GJ. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis. 1996;27:489-495.
19. Crook ED, Harris J, Oliver B, et al. The effect of enalapril on advanced diabetic nephropathy in African-American females. Ethn Dis. 2001;11:211-216.
20. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.